First Tracks Biotherapeutics, Inc. (TRAX) company profile
TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$47.10−1.60 (-3.29%)
Close on Nov 13, 2026Market cap $1.68BP/E –Yield –
About First Tracks Biotherapeutics
Pharmaceutical Preparations, SIC 2834
First Tracks Biotherapeutics, Inc. is listed on Nasdaq under the ticker TRAX, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- First Tracks Biotherapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 10770 Wateridge Circle, Suite 210 92121
- Phone
- (212) 373-3000
- Website
- firsttracksbio.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- TRAX
- Exchange
- Nasdaq
- IPO date
- Apr 6, 2026
- Shares outstanding
- 36M, Aug 7, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2091349
- CUSIP
- 337185102
- ISIN
- US3371851029
- FIGI
- BBG020RF4QV8
- Share class FIGI
- BBG020RF4R28
- LEI
- 529900CGIGKN4R5RO925
- EIN
- 39-5003207
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel Faga | President, CEO, Director | 496,684 |
| Paul F. Lizzul | Chief Medical Officer | 42,669 |
| Ajim Tamboli | Chief Financial Officer | – |
| Benjamin Stone | Chief Business Officer | 17,262 |
| John A. Orwin | Director | 17,995 |
| J. Anthony Ware | Director | 15,660 |
| Rita Jain | Director | 19,194 |
| John P. Schmid | Director | 37,652 |
| Dennis M. Fenton | Director | 10,995 |
| Magda Marquet | Director | 15,960 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 20, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 3, 2026 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |
| Feb 6, 2026 | Name change | Name changed from Biopharma Company, Inc. to First Tracks Biotherapeutics, Inc. |
See a number that looks wrong?